NCT04642365

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	RO7296682	RO7296682 will be administered as per the schedules specified in the respective arms.
DRUG	Atezolizumab	Atezolizumab will be administered as per the schedules specified in the respective arms.

Timeline

• Start date: 2021-01-04
• Primary completion: 2024-01-04
• Completion: 2024-01-04
• First posted: 2020-11-24
• Last updated: 2025-05-21
• Results posted: 2025-05-21

Locations

10 sites across 6 countries: United States, Australia, Belgium, Canada, Denmark, Spain

Regulatory

• FDA-regulated drug study